Reata Pharmaceuticals Inc (NASDAQ:RETA) major shareholder James W. Traweek, Jr. bought 17,000 shares of the stock in a transaction dated Saturday, December 29th. The shares were purchased at an average cost of $28.47 per share, for a total transaction of $483,990.00. Following the completion of the transaction, the insider now directly owns 35 shares of the company’s stock, valued at $996.45. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Shares of Reata Pharmaceuticals Inc (NASDAQ RETA) opened at $28.32 on Monday. The company has a market capitalization of $739.52, a price-to-earnings ratio of -18.51 and a beta of -3.06. Reata Pharmaceuticals Inc has a 12-month low of $19.48 and a 12-month high of $40.88. The company has a debt-to-equity ratio of -0.15, a current ratio of 3.18 and a quick ratio of 3.18.

Reata Pharmaceuticals (NASDAQ:RETA) last released its quarterly earnings results on Monday, November 13th. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.11). The company had revenue of $12.60 million during the quarter, compared to analyst estimates of $12.54 million. The firm’s revenue for the quarter was up .0% compared to the same quarter last year. equities analysts anticipate that Reata Pharmaceuticals Inc will post -1.91 earnings per share for the current fiscal year.

A number of equities analysts have recently weighed in on the company. Robert W. Baird reaffirmed a “buy” rating and set a $47.00 target price on shares of Reata Pharmaceuticals in a research report on Tuesday, October 24th. Zacks Investment Research raised Reata Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 24th. ValuEngine lowered Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. Jefferies Group reaffirmed a “buy” rating and set a $44.00 target price on shares of Reata Pharmaceuticals in a research report on Friday, October 6th. Finally, Leerink Swann assumed coverage on Reata Pharmaceuticals in a research report on Wednesday, September 13th. They set an “outperform” rating and a $43.00 target price on the stock. Three investment analysts have rated the stock with a sell rating and eight have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $54.71.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Emerald Advisers Inc. PA raised its position in Reata Pharmaceuticals by 40.1% in the 3rd quarter. Emerald Advisers Inc. PA now owns 569,416 shares of the company’s stock valued at $17,709,000 after buying an additional 162,990 shares during the last quarter. Emerald Mutual Fund Advisers Trust raised its position in Reata Pharmaceuticals by 60.9% in the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 473,051 shares of the company’s stock valued at $14,712,000 after buying an additional 179,124 shares during the last quarter. FMR LLC raised its position in Reata Pharmaceuticals by 74.4% in the 2nd quarter. FMR LLC now owns 414,491 shares of the company’s stock valued at $13,114,000 after buying an additional 176,885 shares during the last quarter. Vanguard Group Inc. raised its position in Reata Pharmaceuticals by 109.6% in the 2nd quarter. Vanguard Group Inc. now owns 295,540 shares of the company’s stock valued at $9,350,000 after buying an additional 154,515 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its position in Reata Pharmaceuticals by 78.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 232,562 shares of the company’s stock valued at $7,359,000 after buying an additional 101,969 shares during the last quarter. 29.58% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Reata Pharmaceuticals Inc (RETA) Major Shareholder James W. Traweek, Jr. Purchases 17,000 Shares” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The original version of this piece can be viewed at https://www.thecerbatgem.com/2018/01/01/reata-pharmaceuticals-inc-reta-major-shareholder-james-w-traweek-jr-purchases-17000-shares.html.

About Reata Pharmaceuticals

Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.

Insider Buying and Selling by Quarter for Reata Pharmaceuticals (NASDAQ:RETA)

Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.